Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bcr-2015-210208 http://scihub22266oqcxt.onion/10.1136/bcr-2015-210208 C4577716!4577716!26376698     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMJ+Case+Rep 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26376698|t=2015. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome |pdf=|usr=}}{{26376698}} gab.com Text Low-dose ofatumumab for rituximab-resistant nephrotic syndrome JO: BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=26376698 #FOAvip Drug resistant idiopathic nephrotic syndrome (DRNS) remains a therapeutic dilemma. In this pilot study, the efficacy of the new fully humanised, anti-CD20 monoclonal antibody ofatumumab was tested in 4 children with persistence of proteinuria for at least 12?months in spite of a full drug approach (including rituximab). We used a low-dose 2-infusion ofatumumab model (300+700?mg/1.73?m2 2?weeks apart) using specified premedication. Transient normalisation of proteinuria (persisting for 2?months) was achieved in 1 child while another presented stable remission after 12?months; both had normal renal function. The outcome was not modified in the remaining 2 children presenting an impaired renal function. These results demonstrate that low-dose ofatumumab may induce remittance of proteinuria in children with a long story of DRNS and normal renal function. Further studies are needed to test whether higher doses of ofatumumab can also modify proteinuria in patients with impaired renal function. Twit Text FOAVip Low-dose ofatumumab for rituximab-resistant nephrotic syndrome ????BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=26376698 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26376698 #FOAvip English Wikipedia <ref>{{Cite pmid|26376698}}</ref> Low-dose ofatumumab for rituximab-resistant nephrotic syndrome #MMPMID26376698 Bonanni A; Rossi R; Murtas C; Ghiggeri GM BMJ Case Rep 2015[]; 2015 (ä): ä PMID26376698show ga Drug resistant idiopathic nephrotic syndrome (DRNS) remains a therapeutic dilemma. In this pilot study, the efficacy of the new fully humanised, anti-CD20 monoclonal antibody ofatumumab was tested in 4 children with persistence of proteinuria for at least 12?months in spite of a full drug approach (including rituximab). We used a low-dose 2-infusion ofatumumab model (300+700?mg/1.73?m2 2?weeks apart) using specified premedication. Transient normalisation of proteinuria (persisting for 2?months) was achieved in 1 child while another presented stable remission after 12?months; both had normal renal function. The outcome was not modified in the remaining 2 children presenting an impaired renal function. These results demonstrate that low-dose ofatumumab may induce remittance of proteinuria in children with a long story of DRNS and normal renal function. Further studies are needed to test whether higher doses of ofatumumab can also modify proteinuria in patients with impaired renal function. äLow-dose ofatumumab for rituximab-resistant nephrotic syndrome (epmc).pdf DeepDyve Pubget Overpricing